Israeli-based specialist pharmaceutical firm Foamix Pharmaceutical is set to initiate a third Phase III clinical trial in the US to investigate FMX101 for the treatment of moderate-to-severe acne.
The additional Phase III trial will be based on the results obtained from two prior Phase III 04 and 05 trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
FMX101 is a 4% minocycline foam being developed for the treatment of moderate-to-severe acne.
The third Phase III trial will evaluate FMX101 for a period of 12 weeks in approximately 1,500 patients at 80 clinical sites.
The co-primary efficacy endpoints are mean change of inflammatory lesion count from baseline and proportion of patients with improvement.
Foamix chief executive officer Dov Tamarkin said: "Based on our analysis of the efficacy results from Trials 04 and 05, we plan to conduct a third trial to validate the results, with the same co-primary endpoints and enrolment criteria but with a substantially increased sample size.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"We intend to begin enrolling patients in this third trial mid-year."
The top-line results from the prior double-blind, randomised, placebo-controlled Phase III trials were found to be favourable.
Conducted in a total of 961 patients over 12 weeks, the trials showed that FMX101 was safe and well tolerated, with no drug-related serious adverse events.
The co-primary endpoints of the trials were similar to that of the third trial, while the secondary endpoints included measure of decrease in non-inflammatory lesion count at week 12 and percentage changes in the inflammatory lesion count at weeks three, six, nine and 12.
Foamix plans to submit a new drug application (NDA) for FMX101 in the second half of next year, based on the results from the third Phase III trial.
